EASD: Low-Dose Aspirin Tied to Lower Risk for New Diabetes in Older Adults
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 5, 2023 -- Aspirin treatment reduces the risk for incident diabetes in older adults, according to a study to be presented at the annual meeting of the European Association for the Study of Diabetes, held from Oct. 2 to 6 in Hamburg, Germany.
Sophia Zoungas, Ph.D., from Monash University in Melbourne, Australia, and colleagues investigated the treatment effect of low-dose aspirin on incident diabetes and fasting plasma glucose (FPG) levels among adults aged 65 years. and older. The participants (16,209 adults) were randomly assigned (1:1) to 100 mg daily enteric-coated aspirin or placebo.
The researchers found that during a median follow-up of 4.7 years, incident diabetes cases were identified in 459 participants in the aspirin group and 536 in the placebo group. The aspirin group had a lower risk for incident diabetes (hazard ratio, 0.85; P = 0.01) and a slower rate of increase in FPG (difference in annual FPG change, −0.006 mmol/L; P = 0.004).
“Given the increasing prevalence of type 2 diabetes among older adults, the potential for anti-inflammatory agents like aspirin to prevent type 2 diabetes or improve glucose levels needs further study,” the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.